Nov. 5; (c) approval of minutes Oct. 15. - Action items: (a) local share account resolution; (b) shared use path agreement with Blue Green Corridor project; (c) 2026 budget — proposed budget. - Old ...
NYSE: VOYG] ("Voyager" or the "Company"), today announced financial results for the third quarter 2025. Delivered net sales ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...
Induced significant tumor regression in vivo without causing systemic cytokine release, indicating favorable safety profile ...
Ginkgo Bioworks announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium ...
KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its global, Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback